Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14026775 | 0.90 | KDM4E (0.36) | KDM4EHSD17B10 | |
| SCHEMBL2955364 | 0.90 | VCAM1 (0.36) | KDM4EHSD17B10 | |
| SCHEMBL14026777 | 0.87 | KCNQ3 (0.35) | — | |
| SCHEMBL2949211 | 0.87 | VCAM1 (0.34) | — | |
| SCHEMBL8269971 | 0.85 | VCAM1 (0.31) | GCKKDM4EHSD17B10 | |
| SCHEMBL8271434 | 0.85 | VCAM1 (0.37) | ALDH1A1HPGD | |
| SCHEMBL2947817 | 0.84 | VCAM1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL2958952 | 0.84 | VCAM1 (0.46) | ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL2951229 | 0.84 | VCAM1 (0.30) | — | |
| SCHEMBL2947868 | 0.84 | KCNQ3 (0.42) | KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791814-B1 | ORTHO-SUBSTITUTED PENTAFLUOROSULFANYL BENZENES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS SYNTHESIS INTERMEDIATES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-06-29 | — | — | EP | disclosed |
| US-7763661-B2 | Ortho-substituted pentafluorosulfanyl benzenes, method for the production thereof and their use as synthesis intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-07-27 | — | — | US | disclosed |
| US-7763661-B2 | Ortho-substituted pentafluorosulfanyl benzenes, method for the production thereof and their use as synthesis intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-07-27 | — | — | US | disclosed |
| US-7763661-B2 | Ortho-substituted pentafluorosulfanyl benzenes, method for the production thereof and their use as synthesis intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-07-27 | — | — | US | disclosed |
| EP-1791813-B1 | PENTAFLUOROSULFANYLPHENYL-SUBSTITUTED BENZOYLGUANIDINES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT OR DIAGNOSTIC AGENT, AND A MEDICAMENT CONTAINING THESE COMPOUNDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-04-29 | — | — | EP | disclosed |
| US-7446225-B2 | Pentafluorosulfanylphenyl-substituted benzoylguanidines, method for the production thereof, their use as a medicament or diagnostic agent, and a medicament containing these compounds | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-11-04 | — | — | US | disclosed |
| US-7446225-B2 | Pentafluorosulfanylphenyl-substituted benzoylguanidines, method for the production thereof, their use as a medicament or diagnostic agent, and a medicament containing these compounds | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-11-04 | — | — | US | disclosed |
| US-7446225-B2 | Pentafluorosulfanylphenyl-substituted benzoylguanidines, method for the production thereof, their use as a medicament or diagnostic agent, and a medicament containing these compounds | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-11-04 | — | — | US | disclosed |
| US-20070259963-A1 | Pentafluorosulfanylphenyl-substituted benzoylguanidines, method for the production thereof, their use as a medicament or diagnostic agent, and a medicament containing these compounds | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259963-A1 | Pentafluorosulfanylphenyl-substituted benzoylguanidines, method for the production thereof, their use as a medicament or diagnostic agent, and a medicament containing these compounds | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259963-A1 | Pentafluorosulfanylphenyl-substituted benzoylguanidines, method for the production thereof, their use as a medicament or diagnostic agent, and a medicament containing these compounds | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259943-A1 | ORTHO-SUBSTITUTED PENTAFLUOROSULFANYL BENZENES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS SYNTHESIS INTERMEDIATES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259943-A1 | ORTHO-SUBSTITUTED PENTAFLUOROSULFANYL BENZENES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS SYNTHESIS INTERMEDIATES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259943-A1 | ORTHO-SUBSTITUTED PENTAFLUOROSULFANYL BENZENES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS SYNTHESIS INTERMEDIATES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| WO-2006027130-A1 | PENTAFLUOROSULFANYLPHENYL-SUBSTITUTED BENZOYLGUANIDINES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT OR DIAGNOSTIC AGENT, AND A MEDICAMENT CONTAINING THESE COMPOUNDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259943-A1 | ORTHO-SUBSTITUTED PENTAFLUOROSULFANYL BENZENES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS SYNTHESIS INTERMEDIATES | PFAS, DDT, PNPO | GCK 2587/4885USP2 1397/4885KDM4E 2274/4885 |
| US-20070259963-A1 | Pentafluorosulfanylphenyl-substituted benzoylguanidines, method for the production thereof, their use as a medicament or diagnostic agent, and a medicament containing these compounds | FANCI, SLCO1B1, SLCO1B3 | GCK 741/4885USP2 915/4885KDM4E 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.